Treating Together: Navigating Treatment Decisions in Relapsed NPM1-Mutant AML: Practical Insights for Clinical Care
Share
Subscribe
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) in this Targeted Oncology podcast. The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.
Dr. Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment selection versus minimal residual disease (MRD) monitoring, noting that NPM1 was previously considered undruggable but now has two FDA-approved menin inhibitors: revumenib and ziftomenib.
Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.
Dr Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment selection versus minimal residual disease (MRD) monitoring, noting that NPM1 was previously considered undruggable but now has two FDA-approved menin inhibitors: revumenib and ziftomenib.